Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
- 1 April 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (537)
- https://doi.org/10.1126/scitranslmed.aaz3577
Abstract
Tumors with high mutational burden (TMB) tend to be responsive to immune checkpoint blockade (ICB) because there are neoantigens available for targeting by reinvigorated T cells, whereas those with low TMB demonstrate limited clinical responses. To determine whether antigen-specific T cell responses can be elicited after treatment with ICB in cancers that have a low TMB, we conducted a clinical trial with ipilimumab in 30 patients with metastatic castration-resistant prostate cancer. We identified two distinct cohorts by survival and progression times: “favorable” (n = 9) and “unfavorable” (n = 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.Keywords
Funding Information
- Prostate Cancer Foundation
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- Parker Institute for Cancer Immunotherapy
- Parker Institute for Cancer Immunotherapy
This publication has 35 references indexed in Scilit:
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2017
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2014
- Signatures of mutational processes in human cancerNature, 2013
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012